Doctors say Vytorin cancer link not ruled out
Results from three studies online in The New England Journal of Medicine and presented in Munich show no definitive proof of a cancer risk from the cholesterol drug Vytorin, but editors urge caution until longer follow up. Experts note uncertainty persists about safety and effectiveness.
MENTIONED IN THIS ARTICLE
Munich
Germany
New England Journal of Medicine
Merck
Schering- Plough
Terje Pedersen
Oslo
Norway
Oxford Univer
Sity
England
Richard Peto
Medical Journal
Gordon Tomaselli
Johns Hopkins Hospital
American Heart Association
Smoking riskier for women in heart attack study
Norwegian researchers presented to the European Society of Cardiology report that women who smoke suffer heart attacks about 14 years earlier than non smokers, while men show about a six year gap. The Lillehammer hospital study tracked 1784 patients with first heart attacks and noted age differences after adjusting for risk factors.
MENTIONED IN THIS ARTICLE
Munich
Germany
European Society of Cardiology
Silvia Priori
Pavia
Italy
Priori
Morten Grundtvig
Innlandet Hospital Trust
Lillehammer
Norway
Also Mentioned on This Page
Vytorin
Merck & Co
Schering-Plough Corp
MrCentral.com
Limestone
Business Administration
Computer Science
Social Work
Criminal Justice
Liberal Studies
Aiken
North Augusta
Jefferson Davis
Limestone.edu
Kroger
Jorosalby
Theos
Glaceau
Gwaltney
Kroger Limited PA
Wat